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Transplantation of the Kidney and Liver 
TH. E. STARZL 
In the interval allowed to me, I would like to say first something about renal 
transplantation, and then in the remaining time comment on our results in the new 
field of liver transplantation. My particular emphasis with both organs will be on the 
use of antilymphocyte globulin (ALG) and how the imployment of this substance has 
influenced the transplantation program at the University of Colorado. In doing this I 
shall say nothing about the underlying animal work with antilymphocyte serum (ALS) 
or globulin (ALG) in which these agents were used as the sole immunosuppressive 
therapy, since in the clinical application we have lIsed ALG as an adjuvant drug added 
to treatment with azathioprine and with reduced doses of steroids. 
Kidney transplantation 
First series 
In order to develop some background for the way in which antilymphocyte globulin 
has influenced our results, I would like to briefly summarize our earlier experiences with 
clinical transplantation. Fig. 1 is a life-survival curve established with the seJ;'ies of cases 
treated at the University of Colorado from 1962 until March of 1964. It represents a 
group of patients, in which there is now a minimum followup of considerably more than 
four years and with a maximum followup that goes out to more than 51/2 years. These 
are cases in which the donor-recipient combinations were selected essentially at random 
since there were no effective methods of histocompatibility typing at the time. The only 
selection that was practised, at least in most of these cases, was to insure conformity or 
compatibility of red blood cell types. 
There were 64 patients in this original series, 46 of whom received kidneys from 
familial donors. The other 18 received kidneys from non-related living donors. One 
can see that the highest loss rate was within the first few months, and that after this 
time there was a fairly stable survival. In fact, in the related cases there were only 
3 additional deaths after the first 6 postoperative months, 1 each in the 2nd, 3rd, and 
4th postoperative years, so that in this group of cases there are still 29 out of the original 
46, or some 600/0 of the original recipients still alive. 
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In contrast, there was a much higher earlier death rate after the non-related trans-
plantations and then with a continued delayed attrition until at the present time in the 
5th postoperative year, there are only 2 of these original recipients still alive (Fig. 1). 
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Fig. 1. Life survival curves of 64 patients treated in Denver with renal homotransplantation 
between November 1962 and March 1964. Preoperative histocompatibility testing was not done. 
As of November 1, 1968, a minimum followup of 42/8 and a maximum followup of 6 years 
is available. Note the much better results with intra familial homotransplantation. 
Second series 
At the end of this experience we stopped doing transplantations for about 6 months, 
from March until October of 1964. The reason for this was that it had not been 
possible, at least in our hands, to improve the survival after transplantatiort. The death 
rate in the last half of the aforementioned original seri~s was almost the same as in the 
fun~i ' 
In October of 1964 the program was reopened but with a significant change. Working 
in collaboration with TERASAKI, we tried to select donor-recipient combinations on the 
basis of serologic analysis of histocompatibility antigens. An additional 42 cases ~ere 
compiled between October of 1964 and April of 1966. 25 of these new transplantations 
were intrafamilial. To our disappointment, the ult"imate lo,ss rate' in this series was 
almost exactly the same as it had been previously. About a third of these recipients of 
consanguineous grafts died in the first postoperative year (Fig: 2). 1'his was not parti-
cularly surprising, not only because of the limited sizes of the family donor pools but 
also because of our policy at that time not to exclude anyone from homograft recipienc'y 
solely because we could not find a good match. There was no statisticaHy significan~ 
upgrading of the histocompatibility' matching as determined during this period by 
TERASAKI. 
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Fig. 2. Survival of 42 patients treated with renal homotransplantation between October 1964 
and April 1966. An attempt was made by TERASAKI to select the most compatible donor amongst 
available volunteers. 
In the non-related transplantations there was some improvement in survival, and now 
55% of the patients lived through the 1 postoperative year (Fig. 2). In this group there 
had been an improvement in the histocompatibility matching since it had been possible 
to draw donors from a much larger pool. 
ALG series 
It seemed obvious to us at the end of this trial that the further improvement of results 
was dependent on improvements in immunosuppression. It was at this stage that ALG 
was introduced clinically. 
Dr. PICHLMAYR and others have already discussed how ALS is prepared by immuni-
zation of a heterologous host, how the globulin (ALG) is extracted, and the fact that it 
can be used with intramuscular or intravenous injection. As it has already been emphasi-
zed, proper absorption of the serum, before the globulin is extracted, is an essential 
feature of the preparation of ALG, if it is to be reasonably safe. Dr. PICHLMAYR has 
also told you something about the toxicity of this ALG. 
The ALG that was used from June of 1966 for the 1st year and a half of our study 
is shown in Fig. 3. It was prepared by ammonium sulfate precipitation and consisted of 
y G, T-equine globulin, and often traces of IX globulin. 
The first patients in this series were treated from June of 1966 until the following 
December. There were 20 in all. Inclusion was not on the basis of good histocompati-
bility conformity or match. Of the 20 patients in the series, 1 was lost in the 2nd post-
operative month from a surgical technical accident. The other 19 of these patients are 
still alive after a followup of some 22 to 28 months. Thus the 2 year survival .with 
intra familial transplantation using ALG as an adjuvant agent was 95% (Fig. 4). Since 
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Fig. 3. Electrophoresis and immunoelectrophoresis of absorbed antihumanlymphocyte serum and 
the protein obtained from it by two precipitations with 0.4 saturated ammonium sulphate, two 
dialyses and lyophilization. The final product which was used clinically, consisted almost entirely 
of y G and T-equine globulin. [By permission of Surg. Gynec. Obstet. 124: 1 (1967).] 
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Fig. 4. Survival curve of the first 20 patients treated with antilymphocyte globulin (ALG) 
compared 0 that in 3 previous series of consanguineous transplantation at our institutions. 
Followups in the globulintreated group are 22 to 28 months. The numbers III the upper curve 
indicate the patients at risk for each monthly interval. 
December of 1966, renal transplantation has become a service procedure performed by 
residents, by houseofficers and by fellows. It is a little painful for the senior surgeons 
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to now realize that the houseoHicers or those il1 training have just as good rcsults as 
t hose obtained by thcir scnior colleagues. 
The reason I think for the improvement 111 our results is that with ALG it has been 
possible to usc smaller doses of both azathioprine and steroids. The reduction in the 
latter drug is probably particularly significal1t. All people with extensive experience in 
transplantation have come to realize that the real villain in the picture of rena l trans-
plantation has been prednisone rather than azathioprine. The morbidity in the ALG 
treated patients has been correspondingly less as the requisite steroid doses have been 
decreased. Coincidentally, the renal function in these cases has been better on the 
a verage than in past cases. 
Liver transplantation 
The first trials of liver transplantation in man were made in 1963 in Denver. From 
this time until the summer of 1967 there were a total of 9 such attempts in our institu-
tion, at the Peter Bent Brigham Hospita l in Boston, and by ab~ffoibAr in Paris. In each 
of these cases, the recipient had died within 23 days or less. The causes of death were 
complex but they generally were due either to the failure to provide good homograf~ 
function from the beginning or else failure to retain this function for any significant 
period of time. 
Since the summer of 1967 we have made 9 new attempts at liver transplantation with 
distinctly encouraging although still imperfect results. 4 of these 9 patients are alive 
including the 1 to whom Dr. TERAsAKI alluded. 
(The foregoing portion of the lecture is essentially as presented at the meeting. The 
following account has been largely rewritten to permit a follow up report of 5 months 
longer duration. The statistics for the 9 mentioned cases have thus been brought up to 
date to October 25, 1968.) 
Of the 9 recipients,S have died after periods of 60, 105, 133, 186, and 400 days. The 
other 4 are living after 3, 5, 61/2, 71/2 and 81/2 months. In the 9 cases the indication for 
operation was extrahepatic biliary atresia in 6 and hepatoma in the other 3. 7 of the 
recipients were children and 2 were adults. 
All of the patients who have died develllped the specific complication of partial 
necrosis of the right hepatic lobe. Autopsy studies in 4 of the 5 cases revealed selective 
thrombosis of the right hepatic artery. 
The etiology of this complication is probably a complex one but one factor may have 
been mechanical. Autopsy studies l1 ave shown that failme to resuture the ligaments of 
the homograft to that of the host can result in a downward and medical rotation of the 
right lobe and a consequent kinking of the right hepatic branch (Fig. 5). In subsequent 
cases the falciform and triangular ligaments have been resutured and the regional hepatic 
gangrene has not been seen again. 
So far the longest survival after orthotopic liver transplantation in man has beeli 
400 days. This recipient ultimately died of widespread carcinomatosis from her original 
hepatoma. Another patient who has perfect liver function 6[/2 months post-transplanta-
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Fig. S. Angiographic studies performed in a 5 year old child immediately aher her death from 
head injuries. Dye was injected into the common hepatic artery (CHA) proxim al to the gastro-
duodenal artery (GDA). Left: Initial injection. Note the smooth course of the right hepatic 
artery (RHA). Right: The restraining ligaments of the liver ha\'c been incised, a cholccysto-
duodenostomy performed, and the head of the x-ray table elevated to 60 0 . The right lobe of 
the liver has rotated down and medially. The course of the left hepatic artery is undisturbed. 
However, the right hepatic artery (REA) is now severely kinked where it passes beneath the 
common duct. [B y permission of Ann. Surg. 168: 392 (1968).] 
tion has recently developed evidence of pulmonary metastases. Thus the value of liver 
replacement for the treatment of hepatic malignancy is probably going to be limited by 
the aggressive nature of this disease. 
Conclusion 
The whole picture or organ transplantation has undergone an amazing transformation 
in the last 5 or 6 years to the point where renal transplantation as a method of treating 
terminal renal failure has become a spectacularly successful form of therapy. 
The developments which have made this possible provide a basis in 1968 for attempts 
at transplantation of other vital organs including the liver, heart, and lung. Survival 
after orthotopic liver transplan tation has already been achieved in man for more than 
13 months, and more recently experience with heart transplantation has suggested that 
this procedure also will be of clinical therapeutic value. 
